143 related articles for article (PubMed ID: 35307978)
1. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity.
Duong JK; Nand RA; Patel A; Della Pasqua O; Gross AS
Pharmacol Res Perspect; 2022 Apr; 10(2):e00946. PubMed ID: 35307978
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions.
Loer HLH; Türk D; Gómez-Mantilla JD; Selzer D; Lehr T
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631502
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
Kobayashi M; Kajiwara M; Hasegawa S
J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.
Jung YS; Jin BH; Park MS; Kim CO; Chae D
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):29-40. PubMed ID: 37775990
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
.
Higashimori M; Shimada H; Ichikawa K; Zhou D
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):29-36. PubMed ID: 31657713
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
Gong J; Iacono L; Iyer RA; Humphreys WG; Zheng M
Br J Clin Pharmacol; 2018 Jun; 84(6):1335-1345. PubMed ID: 29469197
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes.
Yang H; Yang L; Zhong X; Jiang X; Zheng L; Wang L
Eur J Pharm Sci; 2022 Oct; 177():106258. PubMed ID: 35840101
[TBL] [Abstract][Full Text] [Related]
12. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
[TBL] [Abstract][Full Text] [Related]
13. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
15. Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling.
Zhou L; Sharma P; Yeo KR; Higashimori M; Xu H; Al-Huniti N; Zhou D
Eur J Pharm Sci; 2019 Nov; 139():105061. PubMed ID: 31479720
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes.
Xu RJ; Kong WM; An XF; Zou JJ; Liu L; Liu XD
Front Pharmacol; 2020; 11():593982. PubMed ID: 33519456
[No Abstract] [Full Text] [Related]
17. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL
Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability.
Zakaria ZH; Fong AYY; Badhan RKS
Pharmaceuticals (Basel); 2018 Jul; 11(3):. PubMed ID: 30049953
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.
Cheng Y; Wang L; Iacono L; Zhang D; Chen W; Gong J; Humphreys WG; Gan J
Br J Clin Pharmacol; 2018 Jan; 84(1):130-141. PubMed ID: 28850715
[TBL] [Abstract][Full Text] [Related]
20. Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.
Karaźniewicz-Łada M; Krzyżańska D; Danielak D; Rzeźniczak J; Główka F; Słomczyński M; Burchardt P
Eur J Clin Pharmacol; 2020 Mar; 76(3):419-430. PubMed ID: 31897532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]